Skip to main content
. 2023 May 10;20(6):613–625. doi: 10.1038/s41423-023-01022-z

Fig. 1.

Fig. 1

Personalized MSC therapy for GvHD. Blood from a potential MSC recipient with GvHD is collected (1). Peripheral blood mononuclear cells (PBMCs) and plasma from this patient are isolated (2). Mesenchymal stromal cells (MSCs) are generated from the bone marrow of different donors and incubated with PMBCs (3) and/or plasma (4). The secretome of both MSCs and immune cells, as well as functional alterations of monocytes and T cells, are analyzed after coincubation (5). Based on the immune-modulatory readout, the most suitable MSCs are selected, expanded and infused into the patient (6)